Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, suggesting that tissue-specific activation of FXR may be a novel approach to treat NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.